{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "health-sciences:medicine:gastroenterology:gi-013",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:52:30.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "hepatology-specialist-agent"
    ],
    "confidence": 0.97,
    "status": "peer-reviewed",
    "modified": "2026-01-11T16:35:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/gastroenterology",
    "type": "definition",
    "difficulty": "advanced",
    "importance": "critical"
  },
  "content": {
    "title": "Hepatic Encephalopathy",
    "summary": "Reversible neuropsychiatric dysfunction in liver disease caused by accumulation of gut-derived neurotoxins (primarily ammonia) bypassing hepatic metabolism",
    "key_points": [
      "Spectrum from subtle cognitive deficits (covert HE) to coma (overt HE grade IV)",
      "Ammonia is key neurotoxin but level does not correlate with severity",
      "Precipitants: Infection, GI bleeding, constipation, sedatives, dehydration, electrolyte abnormalities",
      "West Haven Criteria grades severity (0-IV); Conn score similar",
      "Lactulose is first-line: Target 2-3 soft bowel movements daily",
      "Rifaximin reduces recurrence by 60% - add for recurrent overt HE",
      "Identify and treat precipitating factors - often more important than ammonia treatment",
      "Protein restriction is NOT recommended - maintains muscle mass for ammonia metabolism"
    ],
    "statement": "Hepatic encephalopathy is a reversible neuropsychiatric syndrome caused by accumulation of neurotoxins (primarily ammonia) in patients with liver dysfunction or portosystemic shunting, ranging from subtle cognitive deficits to coma.",
    "explanation": {
      "intuition": "The liver normally detoxifies ammonia (produced by gut bacteria and protein metabolism) into urea for kidney excretion. When the liver is damaged or blood bypasses it through portosystemic shunts, ammonia reaches the brain and causes astrocyte swelling, neurotransmitter changes, and brain dysfunction.",
      "key_insight": "The key to managing HE is identifying and treating the precipitant (infection, bleeding, dehydration, constipation, medications) while reducing ammonia production/absorption. Lactulose works by acidifying the colon (converts NH3 to NH4+ which cannot be absorbed) and promotes catharsis. Rifaximin reduces ammonia-producing bacteria.",
      "technical_details": "Ammonia crosses blood-brain barrier and is metabolized by astrocytes using glutamine synthetase (NH3 + glutamate â†’ glutamine). Glutamine accumulation causes astrocyte swelling and oxidative stress. Ammonia also affects GABA-benzodiazepine receptor complex, contributing to altered consciousness. Other factors include inflammation, manganese accumulation, and false neurotransmitters from aromatic amino acids."
    },
    "definitions_glossary": {
      "hepatic_encephalopathy": "Neuropsychiatric dysfunction due to liver disease and/or portosystemic shunting",
      "overt_he": "Clinically apparent HE with disorientation, asterixis, or decreased consciousness (West Haven II-IV)",
      "covert_he": "Subtle cognitive deficits (minimal HE and grade I) detectable only with psychometric testing",
      "minimal_he": "Abnormalities only on specialized testing; no clinical signs",
      "west_haven_criteria": "Grading system from 0 (no abnormality) to IV (coma)",
      "asterixis": "Flapping tremor of extended wrists; classic sign of HE but not specific",
      "ammonia": "Key neurotoxin; produced by gut bacteria and protein metabolism; cleared by liver urea cycle",
      "lactulose": "Non-absorbable disaccharide; acidifies colon, traps NH4+, promotes catharsis",
      "rifaximin": "Non-absorbed antibiotic reducing ammonia-producing gut bacteria",
      "portosystemic_shunting": "Blood bypassing liver; allows toxins to reach systemic circulation",
      "precipitating_factors": "Conditions triggering HE: infection, GI bleed, constipation, dehydration, medications",
      "tips": "Transjugular intrahepatic portosystemic shunt; can precipitate or worsen HE"
    }
  },
  "clinical_features": {
    "pathophysiology": {
      "mechanism": "Accumulation of neurotoxins (ammonia, mercaptans, GABA, benzodiazepine-like substances) due to hepatic insufficiency and/or portosystemic shunting",
      "ammonia_hypothesis": {
        "production": "Gut bacteria (urease-producing), intestinal glutaminase, muscle metabolism",
        "clearance": "Hepatic urea cycle (impaired in cirrhosis)",
        "brain_effects": [
          "Astrocyte swelling from glutamine accumulation",
          "Altered neurotransmission (GABA, glutamate, dopamine)",
          "Oxidative stress and inflammation",
          "Cerebral edema (mainly acute liver failure)"
        ]
      },
      "classification": {
        "type_a": "HE associated with Acute liver failure",
        "type_b": "HE associated with portosystemic Bypass without intrinsic liver disease",
        "type_c": "HE associated with Cirrhosis and portal hypertension (most common)"
      },
      "precipitating_factors": [
        "Infection/sepsis (most common precipitant)",
        "GI bleeding (protein load + hypovolemia)",
        "Constipation (increased ammonia absorption)",
        "Dehydration/electrolyte abnormalities (hypokalemia, hyponatremia)",
        "Sedatives (benzodiazepines, opioids)",
        "Excessive dietary protein (rarely - usually overemphasized)",
        "Renal failure (decreased urea excretion)",
        "TIPS placement",
        "Portosystemic shunt surgery"
      ]
    },
    "diagnostic_criteria": {
      "west_haven_criteria": {
        "grade_0": "No abnormality (minimal HE only on testing)",
        "grade_i": "Mild: Euphoria/anxiety, shortened attention span, impaired addition/subtraction",
        "grade_ii": "Moderate: Lethargy, disorientation to time, personality change, asterixis",
        "grade_iii": "Severe: Somnolent but arousable, marked confusion, gross disorientation, bizarre behavior",
        "grade_iv": "Coma: No response to verbal; may/may not respond to painful stimuli"
      },
      "clinical_features": [
        "Altered mental status (confusion, disorientation, somnolence)",
        "Asterixis (flapping tremor - also seen in uremia, CO2 retention)",
        "Personality changes, inappropriate behavior",
        "Sleep-wake cycle reversal",
        "Hyperreflexia early, hyporeflexia late",
        "Fetor hepaticus (sweet, musty breath odor)"
      ],
      "laboratory": {
        "ammonia": "Usually elevated but level does not correlate with severity; don't follow serially",
        "exclude_other_causes": "Glucose, electrolytes, creatinine, blood cultures, urinalysis, toxicology"
      },
      "testing_for_covert_he": [
        "Psychometric Hepatic Encephalopathy Score (PHES)",
        "Stroop smartphone app",
        "Critical flicker frequency",
        "Number connection tests"
      ],
      "imaging": "CT/MRI to exclude structural lesions (subdural, stroke); not diagnostic for HE"
    },
    "treatment_options": {
      "general_principles": [
        "Identify and treat precipitating factor - often most important intervention",
        "Supportive care and monitoring",
        "Consider ICU for grade III-IV (airway protection)",
        "Do NOT restrict protein - maintain nutrition for muscle mass"
      ],
      "first_line_lactulose": {
        "mechanism": "Acidifies colon (traps NH4+), cathartic effect (removes substrate)",
        "dosing": "25-45 mL PO q1-2h until bowel movement, then titrate to 2-3 soft stools/day",
        "enema": "For patients unable to take PO: 300 mL lactulose + 700 mL water retention enema",
        "maintenance": "Continue indefinitely for secondary prophylaxis"
      },
      "add_on_rifaximin": {
        "indication": "Recurrent overt HE despite lactulose",
        "dosing": "550 mg PO BID",
        "efficacy": "Reduces recurrence by ~60% when added to lactulose",
        "cost": "Main barrier; significantly more expensive than lactulose alone"
      },
      "alternative_therapies": {
        "neomycin": "Rarely used now due to nephrotoxicity and ototoxicity",
        "metronidazole": "Limited use due to side effects with chronic use",
        "zinc_supplementation": "May help; zinc is cofactor for urea cycle enzymes",
        "lola": "L-ornithine L-aspartate; some evidence for benefit"
      },
      "avoid": [
        "Protein restriction (harms more than helps)",
        "Benzodiazepines (unless treating alcohol withdrawal)",
        "Opioids (if possible)",
        "Overdiuresis (causes dehydration and hypokalemia)"
      ]
    }
  },
  "skos": {
    "prefLabel": "Hepatic Encephalopathy",
    "altLabel": [
      "HE",
      "Portosystemic encephalopathy",
      "Hepatic coma"
    ],
    "definition": "Neuropsychiatric syndrome caused by liver dysfunction and accumulation of neurotoxins, characterized by altered consciousness, cognitive deficits, and motor abnormalities",
    "broader": [
      "health-sciences:medicine:gastroenterology:cirrhosis-complications"
    ],
    "narrower": [
      "health-sciences:medicine:gastroenterology:overt-hepatic-encephalopathy",
      "health-sciences:medicine:gastroenterology:minimal-hepatic-encephalopathy"
    ],
    "related": [
      "health-sciences:medicine:gastroenterology:gi-012-cirrhosis-definition",
      "health-sciences:medicine:neurology:metabolic-encephalopathy",
      "health-sciences:medicine:gastroenterology:acute-liver-failure"
    ]
  },
  "medicalCode": {
    "snomedCt": {
      "conceptId": "13920009",
      "preferredTerm": "Hepatic encephalopathy",
      "hierarchy": "Disorder of nervous system"
    },
    "icd10": {
      "code": "K72.9",
      "description": "Hepatic failure, unspecified with coma",
      "subcodes": [
        "K72.90 - Hepatic failure, unspecified without coma",
        "K72.91 - Hepatic failure, unspecified with coma"
      ]
    },
    "icd11": {
      "code": "DB91.0",
      "description": "Hepatic encephalopathy"
    },
    "mesh": {
      "descriptorUI": "D006501",
      "descriptorName": "Hepatic Encephalopathy",
      "treeNumbers": ["C06.552.308", "C10.228.140.490"]
    }
  },
  "pedagogical": {
    "learning_objectives": [
      "Recognize clinical features of HE from subtle cognitive changes to coma",
      "Apply West Haven Criteria for grading HE severity",
      "Identify common precipitating factors and investigate for them",
      "Prescribe and titrate lactulose appropriately",
      "Know when to add rifaximin for recurrent HE",
      "Understand why protein restriction is NOT recommended"
    ],
    "clinical_pearls": [
      "Ammonia level does NOT correlate with HE severity - diagnose clinically",
      "Finding and treating the precipitant is often more important than ammonia-lowering therapy",
      "Infection is the most common precipitant - always check for SBP, UTI, pneumonia",
      "Asterixis is classic but not specific - also seen in uremia, respiratory failure, drug toxicity",
      "Lactulose goal is 2-3 soft stools daily - underdosing is common",
      "Rifaximin is expensive but reduces HE recurrence by 60% - save for recurrent overt HE",
      "Do NOT restrict dietary protein - muscle mass is needed for peripheral ammonia metabolism",
      "TIPS can precipitate or worsen HE due to increased portosystemic shunting"
    ],
    "board_yield": {
      "step1_concepts": [
        "Ammonia metabolism and urea cycle",
        "Blood-brain barrier and astrocyte function",
        "GABA-benzodiazepine receptor complex"
      ],
      "step2_concepts": [
        "West Haven grading",
        "Precipitant identification",
        "Lactulose mechanism and dosing"
      ],
      "step3_concepts": [
        "Rifaximin addition for recurrence",
        "Covert HE screening",
        "TIPS-related HE management"
      ],
      "common_questions": [
        "Cirrhotic with confusion - first step?",
        "Mechanism of lactulose?",
        "When to add rifaximin?"
      ]
    }
  },
  "prerequisites": [
    "health-sciences:medicine:gastroenterology:gi-012-cirrhosis-definition",
    "health-sciences:medicine:biochemistry:ammonia-metabolism",
    "health-sciences:medicine:neurology:altered-mental-status"
  ],
  "related_concepts": [
    "health-sciences:medicine:gastroenterology:gi-012-cirrhosis-definition",
    "health-sciences:medicine:gastroenterology:spontaneous-bacterial-peritonitis",
    "health-sciences:medicine:gastroenterology:tips-procedure",
    "health-sciences:medicine:neurology:metabolic-encephalopathy"
  ],
  "evidence": {
    "citations": [
      {
        "reference": "Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by AASLD and EASL. Hepatology 2014;60:715-735",
        "doi": "10.1002/hep.27210",
        "level_of_evidence": "AASLD/EASL Practice Guidelines"
      },
      {
        "reference": "Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-1081",
        "doi": "10.1056/NEJMoa0907893",
        "level_of_evidence": "Randomized Controlled Trial"
      }
    ],
    "confidence_rationale": "Based on AASLD/EASL guidelines and landmark RCT"
  },
  "learning_objectives": [
    "Recognize HE clinical features",
    "Grade severity with West Haven",
    "Identify precipitants",
    "Prescribe lactulose appropriately",
    "Know rifaximin indications"
  ],
  "clinical_pearls": [
    "Ammonia level doesn't correlate with severity",
    "Treat the precipitant",
    "Infection is #1 precipitant",
    "Lactulose: 2-3 stools daily",
    "Don't restrict protein"
  ],
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-11T16:35:00.000Z",
    "sources": [
      {
        "source": "Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by AASLD and EASL. Hepatology 2014",
        "type": "clinical_guideline",
        "year": 2014,
        "relevance": "AASLD/EASL HE guidelines"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2022,
        "isbn": "978-1264268504",
        "relevance": "Comprehensive medical reference"
      },
      {
        "source": "UpToDate. Hepatic encephalopathy. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2024,
        "relevance": "Evidence-based clinical decision support"
      }
    ]
  },
  "quality_assessment": {
    "content_quality_score": 0.96,
    "completeness": 0.97,
    "accuracy": 0.98,
    "clinical_relevance": 0.99,
    "pedagogical_value": 0.95,
    "last_quality_review": "2026-01-11T16:35:00.000Z",
    "reviewer": "quality-agent"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Hepatic_encephalopathy",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1138617"
}